Start here if you're new
what it is
Mettler-Toledo makes the scales, balances, pipettes, and lab tools companies use when being wrong is expensive.
how it gets paid
Last year Mettler-Toledo made $4.0B in revenue. Laboratory instruments was the main engine at $2.24B, or 56% of sales.
why it's growing
Revenue grew ~4.0% last year. Near-term quarters can still feel soft (tariffs, muted demand) even when FY is up modestly.
what just happened
Mettler-Toledo just delivered a 5.03% earnings beat, with last reported EPS of $13.36 versus $12.72 expected.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
95/100 earnings predictability — you can trust these numbers
33.8x trailing p/e — you're paying up for this one
85.0% return on capital — a money-printing machine
xvary composite: 70/100 — average
What they do
Mettler-Toledo makes the scales, balances, pipettes, and lab tools companies use when being wrong is expensive.
This business wins because your lab does not casually swap out a validated balance or pH meter. Once your process is built around Mettler-Toledo, changing vendors means retesting work, retraining staff, and risking mistakes. The numbers show the pricing power: 33.5% operating margin (operating margin → profit after running the business → this company keeps about 34 cents of every sales dollar before interest and taxes) and 95 earnings predictability.
How they make money
$4.0B
annual revenue · their business grew +4.0% last year
Laboratory instruments
$2.24B
Industrial instruments
$1.56B
Food retailing
$0.20B
The products that matter
precision lab equipment
Lab Instruments & Software
55% of sales · $2.2B
This is the core business. It generates 55% of total sales, or about $2.2B, from life sciences customers that care about compliance, accuracy, and workflow more than shaving a little off the purchase order.
largest segment
factory measurement systems
Industrial Weighing & Inspection
40% of sales · $1.6B
Roughly 40% of revenue, or $1.6B, comes from production environments like pharmaceutical and semiconductor lines. That matters because replacement cycles here can pause, but they do not disappear.
onshoring exposure
commercial weighing
Food Retail Scales
5% of sales · $0.2B
Only about 5% of revenue, or $0.2B, comes from food retail. It is the steady corner of the portfolio, but not the part that explains a premium multiple.
small contributor
Key numbers
85.0%
return on capital
Return on capital → profit from the money used in the business → Mettler-Toledo turns capital into profit at a rate most companies do not approach.
33.5%
operating margin
Operating margin → profit after running the business → this company keeps about one-third of sales before financing and taxes.
95
earnings predictability
Earnings predictability → how steady profits have been historically → you are buying consistency, which is why the stock gets a premium multiple.
33.8x
trailing p/e
P/E → price versus last year's earnings → you are paying up for quality, so execution has to stay clean.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- price stability 65 / 100
- long-term debt $2.1B (7% of capital)
- net profit margin 23.0% — keeps 23 cents of every dollar in revenue
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in MTD 3 years ago → it's now worth $9,360.
The index would have given you $14,770.
source: institutional data · total return
What just happened
beat estimates
Mettler-Toledo just delivered a 5.03% earnings beat, with last reported EPS of $13.36 versus $12.72 expected.
Value Line shows 2025 EPS rising to $42.15 from $41.11 in 2024, and 2026 is modeled at $45.85. There is a source mismatch on the latest quarter: EDGAR data provided here lists revenue of $2.9B and EPS of $28.12, while consensus lists the latest EPS at $13.36, so the beat is the cleanest number to trust.
~$1.0B
quarter revenue (approx.)
$13.36
eps
59.2%
gross margin
the number that mattered
The number that mattered was the 5.03% EPS beat, because a 33.8x stock has to keep proving the premium is earned every quarter.
-
mettler-toledo likely finished 2025 on a fairly weak note.
-
indeed, if management’s early-november outlook was right, the ohio-based maker of precision metrology equipment earned between $12.68 and $12.88 a share on an adjusted basis in the fourth quarter of last year, up just 2%–4% from 2024’s $12.41 tally.according to leadership, tariff-related costs likely clipped five percentage points from bottom-line growth in the period. end-market demand also probably remained fairly muted, amid a high level of economic uncertainty and increased geopolitical tensions. (note: the company was scheduled to release fourth-quarter and full-year 2025 results shortly after we went to press.) the company’s initial 2026 view is positive.
-
adjusted earnings are seen rising 8%–9%, on top of what was likely a 2%–3% advance last year.
-
comparisons become a bit easier, as mettler largely laps 2025’s step-up in tariffs.too, the company ought to benefit from a gradual improvement in market conditions and the corresponding return of a more-normal product replacement cycle among its thousands of customers around the globe.
-
mettler remains a compelling long-term investment play on a number of potentially durable tailwinds.among them is an ongoing push to onshore critical industries, such as pharmaceutical and semiconductor production, by not only the u.s. and its allies but also more adversarial countries. this mantra of increased self reliance should drive strong demand for the enabling tools that mettler supplies, especially since they’re generally not subject to export controls and are typically small-ticket items, below the level of stringent budgetary review. another plus for the company is the increased focus of late on improving the productivity of labs through the use of workflow tools like mettler’s labx offering. shares of mettler-toledo remain a timely selection for relative yearahead price performance (2: above average).
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is tariffs staying embedded in the cost structure while growth stays merely okay.
high
persistent tariff drag
Management called tariffs a persistent 4% headwind to adjusted EPS growth. That is a real tax on an otherwise steady earnings story.
about 4% of EPS growth is already gone before demand does anything surprising.
med
china and geopolitical demand swings
International operations, especially in China, face uneven demand and higher geopolitical friction. For an industrial and life sciences supplier, that means orders can slip without the underlying business breaking.
a significant piece of global revenue can turn lumpy even if end demand does not disappear.
med
replacement cycle stays slow
Part of the 2026 optimism rests on customers returning to a more normal replacement pattern. If labs and factories keep stretching equipment life, revenue can stay closer to the recent 4% pace.
that would make the stock's 33.8x earnings multiple look more expensive, not less.
low
buyback support fades
The company is nearing completion of a long-running share repurchase program. If repurchases slow, per-share growth gets less mechanical support.
the business still works, but EPS growth relies more heavily on actual operating improvement.
A business guiding for ~4% sales growth is already giving up 4% of adjusted EPS growth to tariffs. At 33.8x earnings, there is not much padding for another slow quarter.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
q1 2026 earnings report
Expected April 30, 2026. Management pointed to roughly 3% local currency sales growth and EPS of $8.60–$8.75. The first question is whether they clear a low bar cleanly.
metric
full-year 2026 sales growth
The full-year target is about 4% local currency sales growth. If MTD cannot do better than that with easier comparisons, the premium valuation stays under pressure.
risk
tariff drag on EPS
Management's 4% tariff headwind is the cleanest kill-switch on the near-term thesis. If that drag worsens, 8%–9% earnings growth gets harder to hit.
trend
split institutional tape
There were 333 buyers versus 318 sellers in 3q2025, with total institutional holdings of 20.5M shares. That's interest, not conviction. Watch whether that gap widens or disappears.
Analyst rankings
earnings predictability
95 / 100
Management gives reliable guidance and the business rarely lurches. In human-speak: analysts trust the numbers, even if they are arguing about the price.
short-term outlook
2
The stock is still viewed as an above-average candidate for relative price performance over the next year. That is a polite way of saying the street still respects the business after the selloff.
source: institutional data
Institutional activity
333 buyers vs. 318 sellers in 3q2025. total institutional holdings: 20.5M shares.
source: institutional data
Price targets
3-5 year target range
$1097
$2020
$1426
current price
$1970
target midpoint · +38% from current · 3-5yr high: $2365 (+65% · 13% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive